• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

    10/23/23 7:45:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email

    NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs.

    Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawaiian Airlines, and Kajima Corporation. Mr. Tung formerly served as Senior Vice President and General Counsel of the World Bank, Secretary General of the International Centre of the Settlement of Investment Disputes (ICSID), senior partner of O'Melveny & Myers, and Senior Counsellor at Morrison & Foerster.

    "Ko-Yung brings 50 years' experience in corporate governance, international investment, law, economic development, and international business to SEED's Board. His joining is timely as SEED addresses domestic and international opportunities to translate its TPD technology to new lead agents ready for regulatory filings in advance of clinical testing. Ko-Yung will extend his ongoing advice to the SEED Board and Management on navigating increasingly complex legal, governance, and geopolitical issues as we pursue our mission of introducing SEED's TPD technology and platform to improve the quality of life for patients across the globe," said Dr. Lan Huang, Chairman and Chief Executive Officer of BeyondSpring, and Chairman, CEO and Co-Founder of SEED.

    Mr. Tung currently serves as a board member of the Global Health Innovative Technology Fund (GHIT) in Japan with funding from the Gates Foundation, the Japanese government, Wellcome Trust, and large Japan pharmaceutical firms, including Takeda, Astellas, and Eisai. GHIT makes grants to international development partners in the field of Neglected Tropical Diseases. While at the World Bank, Mr. Tung provided legal advice in the establishment of the Global Fund for AIDS, Malaria and Tuberculosis. He has been at the lead of cross-border public policy, including as a member of the Trilateral Commission, U.S. Presidential Commission on United States Pacific Trade and Investment Policy, and Chairman of the Board of Governors of the East-West Center. He is also a member of the Council on Foreign Relations and has been associated with the American Society of International Law, International Bar Association, and Bar of the City of New York. As a distinguished scholar, Mr. Tung has taught at Harvard Law School, Yale Law School, and NYU Law School for many years. Mr. Tung received his education at Harvard College (B.A. in physics, magna cum laude), Harvard Law School (J.D.), and University of Tokyo, Faculty of Law.

    "I have always been committed to helping people with unmet medical problems, whether in new drugs, affordability, or public policy. I am honored to be working closely with SEED's Scientific Co-Founders and our team of seasoned scientists and development experts as SEED transforms its groundbreaking TPD platform into a portfolio of approved drugs to address unmet medical needs. It is inspiring to see SEED's unwavering commitment and leadership to be TPD trailblazers and to raise the quality of life for patients around the world," said Mr. Tung.

    About SEED Therapeutics

    SEED Therapeutics is an innovative biotech company focusing on harnessing and engineering "molecular glues" and targeted protein degradation (TPD) to attack previously undruggable targets. Backed by a comprehensive intellectual property portfolio, SEED Therapeutics' mission is to positively impact human health by creating novel protein degradation therapeutics to treat various severe diseases that currently have limited treatment options for patients and their families. Through ongoing collaborations with world-leading academic experts in the field, SEED Therapeutics is developing a growing pipeline of novel drug candidates on a path to potential clinical and commercial success. SEED has an initial R&D collaboration and investment from Eli Lilly. With today's announcement, SEED's Board of Directors is composed of SEED Chairman, CEO and Co-Founder Dr. Lan Huang, PhD, an ubiquitin ligase expert, biotech entrepreneur, and Chairman, CEO and Co-Founder of BeyondSpring; Dr. James Tonra, PhD, seasoned translational science leader and SEED President and Chief Scientific Officer; Dr. Linus Lin, PhD, drug discovery and development expert and global head of Eli Lilly Chorus; Jackson Tai, corporate governance, finance, and risk expert and recently retired Eli Lilly director; and Ko-Yung Tung, eminent international lawyer, cross-border strategic advisor, and former World Bank General Counsel. Learn more by visiting https://seedtherapeutics.com/.

    About BeyondSpring

    BeyondSpring (NASDAQ:BYSI) is a global clinical-stage biopharmaceutical company focusing on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring's subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform for novel drug development in oncology, neurodegeneration, and virology. Learn more by visiting https://beyondspringpharma.com, and follow us on LinkedIn and Twitter.

    Investor Contact:

    [email protected]

    Media Contact:

    [email protected]



    Primary Logo

    Get the next $BYSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BYSI

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $BYSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kirkby Matthew

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:36 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Huang Lan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:05 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Delaney Brendan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:59:42 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

      Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease progression on 1L PD-1/L1 inhibitors with and without chemotherapy (NCT05599789), with financial support from Merck's (Rahway, NJ USA) Investigator Studies Program and provision of study drug, at the 2

      6/3/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

      FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL. ​​Presentation details are as follows: Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Pli

      5/28/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

      Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED's first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update. "Plinabulin has now been administered to more than 7

      5/12/25 4:30:44 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care